Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities.
Serresi M, Siteur B, Hulsman D, Company C, Schmitt MJ, Lieftink C, Morris B, Cesaroni M, Proost N, Beijersbergen RL, van Lohuizen M, Gargiulo G.
Serresi M, et al. Among authors: gargiulo g.
J Exp Med. 2018 Dec 3;215(12):3115-3135. doi: 10.1084/jem.20180801. Epub 2018 Nov 28.
J Exp Med. 2018.
PMID: 30487290
Free PMC article.